Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
R&D Systems™ Recombinant Human EGFR Fc Chimera Alexa Fluor™ 488 Protein
Click to view available options
Quantity:
20 μg
Description
Measured by flow cytometry for its ability to bind anti-human EGFR Monoclonal Antibody conjugated beads. The concentration of Recombinant Human EGFR Fc-tag Alexa Fluor™ 488 (Catalog # AFG344) that produces 50% of the binding response is 8.00-120 ng/mL.
Specifications
Specifications
Accession Number | CAA25240.1 |
For Use With (Application) | Bioactivity |
Formulation | Supplied as a 0.2 μm filtered solution in PBS with BSA as a carrier protein. |
Gene ID (Entrez) | 1956 |
Molecular Weight (g/mol) | M.W.-observed: 118-134 kDa, under reducing conditions., M.W.-theroretical: 95 kDa (monomer) |
Quantity | 20 μg |
Source | Mouse myeloma cell line, NS0-derived human EGFR protein Human EGFR (Leu25-Ser645) (C-terminus) Accession # CAA25240.1 IEGRMD Human IgG1 (Pro100-Lys330) (N-terminus) |
Storage Requirements | Protect from light. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 6 months from date of receipt, -20°C to -70°C as supplied. 1 month, 2°C to 8°C under sterile conditions after opening. 3 months, -20°C to -70°C under sterile conditions after opening. |
Endotoxin Concentration | <1.0 EU / 1 μg of the protein by the LAL method. |
Gene Alias | avian erythroblastic leukemia viral (v-erb-b) oncogene homolog, cell growth inhibiting protein 40, cell proliferation-inducing protein 61, EC 2.7.10, EC 2.7.10.1, EGF R, epidermal growth factor receptor, epidermal growth factor receptor (avian erythroblastic leukemia viral (v-erb-b)oncogene homolog), ErbB, ErbB1, ERBB1PIG61, HER1, HER-1, mENA, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1 |
Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction